HENGRUI PHARMA (01276) announced that the company recently received a Drug Clinical Trial Approval Notice for SHR-1049 Injection issued by the National Medical Products Administration, with clinical trials scheduled to commence in the near future.
SHR-1049 Injection is an innovative anti-tumor drug independently developed by the company, intended for the treatment of advanced solid tumors.
According to inquiries, there are currently no similar drugs approved for marketing either domestically or internationally.
As of now, the cumulative R&D investment for the SHR-1049 Injection related project amounts to approximately 26 million yuan (unaudited).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.